EA201892172A1 - Вакцина для лечения гепатита b на основе инактивированных цельных рекомбинантных клеток hansenula, которые экспрессируют hbsag и hbcag - Google Patents

Вакцина для лечения гепатита b на основе инактивированных цельных рекомбинантных клеток hansenula, которые экспрессируют hbsag и hbcag

Info

Publication number
EA201892172A1
EA201892172A1 EA201892172A EA201892172A EA201892172A1 EA 201892172 A1 EA201892172 A1 EA 201892172A1 EA 201892172 A EA201892172 A EA 201892172A EA 201892172 A EA201892172 A EA 201892172A EA 201892172 A1 EA201892172 A1 EA 201892172A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hansenula
hbcag
hepatitis
inactivated
cell
Prior art date
Application number
EA201892172A
Other languages
English (en)
Inventor
Хэму Ван
Чанхуа Ван
Цзюнь Ян
Original Assignee
Хэму Ван
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хэму Ван filed Critical Хэму Ван
Publication of EA201892172A1 publication Critical patent/EA201892172A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/165—Yeast isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01023—Orotidine-5'-phosphate decarboxylase (4.1.1.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/78—Hansenula

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Представлена вакцина для лечения гепатита B на основе инактивированной цельной рекомбинантной клетки Hansenula, которая экспрессирует HBsAg и HBcAg. HBsAgVLP и HBcAgVLP, экспрессируемые в рекомбинантной клетке Hansenula, применяются в качестве антигенов, аминокислотная последовательность HBsAg, экспрессируемая рекомбинантной клеткой Hansenula, предусматривает в общей сложности 19 эпитопов для CTL, аминокислотная последовательность HBcAg, экспрессируемая рекомбинантной клеткой Hansenula, предусматривает в общей сложности 19 эпитопов для CTL, и инактивированная цельная рекомбинантная клетка Hansenula применяется в качестве адъюванта.
EA201892172A 2016-03-25 2017-03-16 Вакцина для лечения гепатита b на основе инактивированных цельных рекомбинантных клеток hansenula, которые экспрессируют hbsag и hbcag EA201892172A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610176389.4A CN105727279B (zh) 2016-03-25 2016-03-25 基于表达HBsAg和HBcAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗
PCT/CN2017/076936 WO2017162092A1 (zh) 2016-03-25 2017-03-16 基于表达HBsAg和HBcAg的失活全重组汉逊酵母细胞的乙肝治疗疫苗

Publications (1)

Publication Number Publication Date
EA201892172A1 true EA201892172A1 (ru) 2019-07-31

Family

ID=56251451

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892172A EA201892172A1 (ru) 2016-03-25 2017-03-16 Вакцина для лечения гепатита b на основе инактивированных цельных рекомбинантных клеток hansenula, которые экспрессируют hbsag и hbcag

Country Status (7)

Country Link
US (1) US11191829B2 (ru)
EP (1) EP3434282A4 (ru)
JP (1) JP6818122B2 (ru)
CN (1) CN105727279B (ru)
EA (1) EA201892172A1 (ru)
SG (1) SG11201808267SA (ru)
WO (1) WO2017162092A1 (ru)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
CA2422506A1 (en) * 2000-09-08 2002-03-14 Epimmune Inc. Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
JP2004175665A (ja) * 2002-11-22 2004-06-24 Japan Science & Technology Agency タンパク質中空ナノ粒子およびそれを用いた薬剤
CN100347287C (zh) * 2004-09-30 2007-11-07 汪和睦 一种重组多形汉逊酵母菌及其构建方法与应用
CN101314761B (zh) * 2007-05-31 2012-05-30 上海生物制品研究所有限责任公司 高拷贝表达重组乙肝表面抗原的毕赤酵母及其制法和应用
CN102038948B (zh) * 2009-10-10 2013-04-10 复旦大学 一种控制乙型肝炎病毒持续性感染的疫苗
CN102462840B (zh) * 2010-11-09 2014-03-19 南通生物科技园开发投资有限公司 乙肝治疗性疫苗
CN102226154B (zh) * 2011-05-12 2013-02-06 中国科学院微生物研究所 具有双重筛选标记的多形汉逊酵母菌及其应用
CN104232661A (zh) * 2013-06-08 2014-12-24 北京天坛生物制品股份有限公司 重组dna序列、酵母菌、乙肝表面抗原制备方法及疫苗
CN105727280B (zh) * 2016-03-25 2021-01-19 汪和睦 基于表达HBsAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗
CN105797151A (zh) * 2016-03-25 2016-07-27 汪和睦 一种基于重组汉逊酵母的高剂量乙型肝炎疫苗

Also Published As

Publication number Publication date
JP2019510089A (ja) 2019-04-11
EP3434282A1 (en) 2019-01-30
WO2017162092A1 (zh) 2017-09-28
CN105727279A (zh) 2016-07-06
CN105727279B (zh) 2019-01-15
US20200376115A1 (en) 2020-12-03
SG11201808267SA (en) 2018-11-29
JP6818122B2 (ja) 2021-01-20
EP3434282A4 (en) 2019-10-30
US11191829B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
EA201791148A1 (ru) Способ определения абсолютных количеств hla-рестриктированных раковых пептидов, образовавшихся в результате естественного процессинга
EA201891415A1 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
MX2021000435A (es) Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
PH12017500727A1 (en) Modified virus-like particles of cmv
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX2017010027A (es) Métodos y composiciones útiles en la generación de respuestas de células t cd8+ no canónicas.
MX2018015755A (es) Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
AR110632A1 (es) Vectores del adenovirus canino
MX2016009189A (es) Vacuna terapeutica potenciadora de inmunidad para virus de papiloma humano (vph) y enfermedades relacionadas.
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
EA202091516A1 (ru) Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EA202092828A1 (ru) Антигенный вариант вируса varicella zoster и его применение
EP4292659A3 (en) Antibodies that neutralize hepatitis b virus and uses thereof
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
EA201892179A1 (ru) ВАКЦИНА ДЛЯ ЛЕЧЕНИЯ ГЕПАТИТА B НА ОСНОВЕ ИНАКТИВИРОВАННЫХ ЦЕЛЬНЫХ РЕКОМБИНАНТНЫХ КЛЕТОК HANSENULA POLYMORPHA, КОТОРЫЕ ЭКСПРЕССИРУЮТ HBsAg
BR112019001115A2 (pt) proteínas de biofusão como vacinas anti-malária
PH12015502353A1 (en) Fusion polypeptides and vaccines
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
MX2022007398A (es) Vacunas contra el virus de la fiebre porcina africana y métodos para usarlas.
MX2020006471A (es) Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
EA201790365A1 (ru) Антигены вируса папилломы человека с хорошими иммунологическими свойствами и содержащая их вакцина
MX2019007924A (es) Vacunas contra la influenza.
BR112017019776A2 (pt) proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos
AR104271A1 (es) Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante